Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00067743
Status:
COMPLETED
Last Update Posted:
2008-01-03
First Post:
2003-08-26
Brief Title:
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome CRPS
Sponsor:
Celgene Corporation
Organization:
Celgene
Study Overview
Official Title:
A Multicenter Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome CRPS
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CRPS
Brief Summary:
This is a multicenter open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mgday orally For each subject the study consists of two phases Pre-treatment phase1 wk and treatment phase 12 wks
Detailed Description:
Once the subject completes the 12 week treatment phase the subject is eligible to continue on the trial Subjects may continue until no further benefit is obtained
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None